Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine L Jones

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Medicinal Chemistry|September 24, 2009
p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progressionNicola M Aston, Paul Bamborough, Jacqueline B Buckton, et al.
Bioorganic & Medicinal Chemistry Letters|July 11, 2008
Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activityRichard Angell, Nicola M Aston, Paul Bamborough, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2007
Biphenyl amide p38 kinase inhibitors 2: Optimisation and SARRichard M Angell, Tony D Angell, Paul Bamborough, et al.
Journal of Medicinal Chemistry|December 22, 2016
Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical ProbePhilip G Humphreys, Paul Bamborough, Chun-Wa Chung, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2008
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modesRichard M Angell, Tony D Angell, Paul Bamborough, et al.
Journal of Medicinal Chemistry|May 4, 2026
Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein DegradersDaniel T Webb, Katherine L Jones, Natsuko Macabuag, et al.
Nature Communications|August 18, 2023
TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulationJonathan D Worboys, Katherine N Vowell, Roseanna K Hare, et al.
Journal of Medicinal Chemistry|August 25, 2015
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory DiseaseKenneth Down, Augustin Amour, Ian R Baldwin, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical ProgressionKatherine L Jones, Dominic M Beaumont, Sharon G Bernard, et al.
Journal of Medicinal Chemistry|November 15, 2022
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432Philip G Humphreys, Niall A Anderson, Paul Bamborough, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Medicinal Chemistry|September 24, 2009
p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progressionNicola M Aston, Paul Bamborough, Jacqueline B Buckton, et al.
Bioorganic & Medicinal Chemistry Letters|July 11, 2008
Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activityRichard Angell, Nicola M Aston, Paul Bamborough, et al.
Bioorganic & Medicinal Chemistry Letters|November 6, 2007
Biphenyl amide p38 kinase inhibitors 2: Optimisation and SARRichard M Angell, Tony D Angell, Paul Bamborough, et al.
Journal of Medicinal Chemistry|December 22, 2016
Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical ProbePhilip G Humphreys, Paul Bamborough, Chun-Wa Chung, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2008
Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modesRichard M Angell, Tony D Angell, Paul Bamborough, et al.
Journal of Medicinal Chemistry|May 4, 2026
Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein DegradersDaniel T Webb, Katherine L Jones, Natsuko Macabuag, et al.
Nature Communications|August 18, 2023
TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulationJonathan D Worboys, Katherine N Vowell, Roseanna K Hare, et al.
Journal of Medicinal Chemistry|August 25, 2015
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory DiseaseKenneth Down, Augustin Amour, Ian R Baldwin, et al.
Journal of Medicinal Chemistry|August 13, 2021
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical ProgressionKatherine L Jones, Dominic M Beaumont, Sharon G Bernard, et al.
Journal of Medicinal Chemistry|November 15, 2022
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432Philip G Humphreys, Niall A Anderson, Paul Bamborough, et al.
Pageof 3